Document Detail


Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.
MedLine Citation:
PMID:  21929536     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There are limited data on the use of ustekinumab outside of clinical trials.
OBJECTIVES: To assess the efficacy and safety of ustekinumab in patients with severe psoriasis attending 10 dermatology centres in the U.K. and Ireland.
METHODS: A retrospective case-note review of 129 patients with psoriasis treated with ustekinumab.
RESULTS: Baseline Psoriasis Area and Severity Index (PASI) was 22·9±10·1 (mean±SD). After 16weeks of treatment with ustekinumab PASI 75 (75% reduction in PASI) was observed in 63·0% (n=80/127) of patients, although four patients required concomitant therapy at the 16-week time point. Previous biologic use did show a small, non-significant trend towards treatment failure. A PASI 75 response was seen in 29·4% (n=5/17) of individuals weighing 90-100kg and treated with the standard 45mg ustekinumab dose compared with PASI 75 of 70·3%, 71·4%, 75·0% and 55·6% for weight groups <80, 80-90, 100-110 and >110kg, respectively (P=0·024). Ustekinumab therapy was well tolerated; serious adverse events were observed in 2·3% (n=3/129) of patients.
CONCLUSIONS: Ustekinumab is a novel biologic agent for psoriasis. When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile.
Authors:
P M Laws; A M Downs; R Parslew; B Dever; C H Smith; J N Barker; B Moriarty; R Murphy; B Kirby; A D Burden; S McBride; A V Anstey; S O'Shea; N Ralph; C Buckley; C E M Griffiths; R B Warren
Related Documents :
21893626 - Long-term opioid therapy reconsidered.
21814776 - Intra-articular injection of hyaluronic acid (mw 1,500-2,000 kda; hyalone) in symptomat...
10820906 - Impact of helicobacter pylori eradication on the development of malt, gland atrophy and...
21952556 - Thalidomide in 42 patients with prurigo nodularis hyde.
24621826 - Effect of electroacupuncture at zusanli (st36) and sanyinjiao (sp6) acupoints on adreno...
16861096 - Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir onc...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of dermatology     Volume:  166     ISSN:  1365-2133     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-03     Completed Date:  2012-03-16     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  189-95     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.
Affiliation:
Dermatological Sciences, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / therapeutic use*
Biological Agents / therapeutic use*
Body Mass Index
Cost of Illness
Dermatologic Agents / therapeutic use*
Female
Humans
Male
Middle Aged
Psoriasis / drug therapy*
Retrospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Biological Agents; 0/Dermatologic Agents; FU77B4U5Z0/ustekinumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Description of the natural course and clinical manifestations of ichthyosis with confetti caused by ...
Next Document:  Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one i...